Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating a bivalent vaccine candidate designed to protect adults aged 60 years and older against Respiratory Syncytial Virus RSV and Human Metapneumovirus HMPV. This Phase 12, randomized, observer-blind, placebo-controlled study involves about 2400 participants and aims to assess the vaccines ability to trigger immune responses and monitor its safety. While several RSV vaccines are approved, there is currently no vaccine for preventing HMPV in older adults. Participants will be assigned to one of 11 groups, receiving different doses of the RSVHMPV vaccine, placebo, or one of four control vaccines. The study includes six dose levels of the RSVHMPV vaccine with predefined antigen ratios. Each participant will be followed for approximately 12 months to allow comprehensive evaluation. The study is conducted across multiple centers and uses a parallel group design. During the study, participants will have blood samples taken at baseline, Day 29, and at 3, 6, 9, and 12 months to measure neutralizing antibodies and immunoglobulin G concentrations against RSV and HMPV. Safety will be monitored through reporting of adverse events shortly after vaccination, for several days post-vaccination, and up to six months or throughout the 12-month study period. Biological tests and medical assessments will also be performed to ensure participant safety and collect detailed data on immune response.